Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study.
Immo WeichertR Romero-OrtunoJ TolonenT SoeC LebusS ChoudhuryC V NadarajahP NanayakkaraM OrrùS Di Sommanull nullPublished in: Journal of clinical pharmacy and therapeutics (2018)
There was no reduction in anticholinergic cognitive burden during the acute admissions. This was the same for all diagnostic subgroups. The anticholinergic load was predominantly caused by medications with a low individual burden. More than 1 in 5 patients not taking anticholinergics on admission were discharged on them and similar numbers saw temporary use of these medications during their admission. More than half of patients on cholinesterase-inhibitors were taking anticholinergics at the same time on admission, potentially directly counteracting their effects.
Keyphrases
- end stage renal disease
- emergency department
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cognitive impairment
- healthcare
- peritoneal dialysis
- prognostic factors
- clinical trial
- randomized controlled trial
- liver failure
- intensive care unit
- patient reported outcomes
- cross sectional
- hepatitis b virus
- african american
- double blind